Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in: Clinical and Translational Medicine 1/2017

Open Access 01-12-2017 | Review

The role of lipids in corneal diseases and dystrophies: a systematic review

Authors: Tyler G. Rowsey, Dimitrios Karamichos

Published in: Clinical and Translational Medicine | Issue 1/2017

Login to get access

Abstract

Corneal diseases are an extensive cause of blindness worldwide and continue to persist as a challenging public health concern. Recently, various lipid-based therapies have been advocated for the modulation of corneal diseases; however, the number of studies is still very limited. Here we focus on developments and challenges on lipid-based therapies for dry eye disease, diabetic neuropathy, and Fuchs’ endothelial corneal dystrophy. All three diseases are highly prevalent conditions and involve corneal stress and inflammation. Lipid-based therapeutics discussed includes cyclooxygenase inhibitors, essential fatty acids, and resolvin analogs. Lipids also show increasing promise as biomarkers of disease and are explored in this review.
Literature
1.
Marfurt CF, Murphy CJ, Florczak JL (2001) Morphology and neurochemistry of canine corneal innervation. Invest Ophthalmol Vis Sci 42(10):2242–2251PubMed
2.
Wang S, Ghezzi CE, Gomes R, Pollard RE, Funderburgh JL, Kaplan DL (2017) In vitro 3D corneal tissue model with epithelium, stroma, and innervation. Biomaterials 112:1–9PubMedCrossRef
3.
4.
Bron AJ, Tomlinson A, Foulks GN, Pepose JS, Baudouin C, Geerling G et al (2014) Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf 12(2 Suppl):S1–S31PubMedCrossRef
5.
Piatigorsky J (2001) Enigma of the abundant water-soluble cytoplasmic proteins of the cornea: the “refracton” hypothesis. Cornea 20(8):853–858PubMedCrossRef
6.
Marfurt CF, Cox J, Deek S, Dvorscak L (2010) Anatomy of the human corneal innervation. Exp Eye Res 90(4):478–492PubMedCrossRef
7.
8.
Pipparelli A, Arsenijevic Y, Thuret G, Gain P, Nicolas M, Majo F (2013) ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells. PLoS ONE 8(4):e62095PubMedPubMedCentralCrossRef
9.
10.
11.
12.
13.
14.
Dana MR, Hamrah P (2002) Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. Adv Exp Med Biol 506(Pt B):729–738PubMedCrossRef
15.
Thakur A, Willcox MD (2000) Contact lens wear alters the production of certain inflammatory mediators in tears. Exp Eye Res 70(3):255–259PubMedCrossRef
16.
17.
Anderson RM, Donnelly MB, Dedrick RF (1990) Measuring the attitudes of patients towards diabetes and its treatment. Patient Educ Couns 16(3):231–245PubMedCrossRef
18.
19.
Parmar IP, Gupta NC, Garg N, Ahluwalia BK, Khurana AK (1986) Corneal blindness—a public health problem. Indian J Public Health 30(4):193–196PubMed
20.
Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106(4):811–816PubMedCrossRef
21.
22.
Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr, Murphy RC et al (2005) A comprehensive classification system for lipids. J Lipid Res 46(5):839–861PubMedCrossRef
23.
Brewitt H, Sistani F (2001) Dry eye disease: the scale of the problem. Surv Ophthalmol 45(Suppl 2):S199–S202PubMedCrossRef
24.
Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ (2015) Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol 9:1719–1730PubMedPubMedCentralCrossRef
25.
(2007) The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5(2):75–92
26.
Sy A, O’Brien KS, Liu MP, Cuddapah PA, Acharya NR, Lietman TM et al (2015) Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). BMC Ophthalmol 15:133PubMedPubMedCentralCrossRef
27.
28.
29.
Amano S, Inoue K (2017) Clinic-based study on Meibomian Gland Dysfunction in Japan. Invest Ophthalmol Vis Sci 58(2):1283–1287PubMedCrossRef
30.
31.
Sambursky R (2016) Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol 10:2337–2343PubMedPubMedCentralCrossRef
32.
Pinna A, Piccinini P, Carta F (2007) Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea 26(3):260–264PubMedCrossRef
33.
34.
Macsai MS (2008) The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 106:336–356PubMedPubMedCentral
35.
Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G (2005) Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci 46(12):4474–4479PubMedCrossRef
36.
Miljanovic B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA (2005) Relation between dietary n−3 and n−6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 82(4):887–893PubMedPubMedCentral
37.
Ohtsuka Y, Okada K, Yamakawa Y, Ikuse T, Baba Y, Inage E et al (2011) Omega-3 fatty acids attenuate mucosal inflammation in premature rat pups. J Pediatr Surg 46(3):489–495PubMedCrossRef
38.
Pflugfelder SC, Farley W, Luo L, Chen LZ, de Paiva CS, Olmos LC et al (2005) Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 166(1):61–71PubMedPubMedCentralCrossRef
39.
Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42(10):2283–2292PubMed
40.
Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D (1999) Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res 19(3):201–211PubMedCrossRef
41.
West-Mays JA, Strissel KJ, Sadow PM, Fini ME (1995) Competence for collagenase gene expression by tissue fibroblasts requires activation of an interleukin 1 alpha autocrine loop. Proc Natl Acad Sci USA 92(15):6768–6772PubMedPubMedCentralCrossRef
42.
Trousdale MD, Zhu Z, Stevenson D, Schechter JE, Ritter T, Mircheff AK (2005) Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis 2:6PubMedPubMedCentralCrossRef
43.
Rashid S, Jin YP, Ecoiffier T, Barabino S, Schaumberg DA, Dana R (2008) Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol-Chic 126(2):219–225CrossRef
44.
Lewin GA, Schachter HM, Yuen D, Merchant P, Mamaladze V, Tsertsvadze A (2005) Effects of omega-3 fatty acids on child and maternal health. Evid Rep Technol Assess (Summ) 118:1–11
45.
Gatell-Tortajada J (2016) Oral supplementation with a nutraceutical formulation containing omega-3 fatty acids, vitamins, minerals, and antioxidants in a large series of patients with dry eye symptoms: results of a prospective study. Clin Interv Aging 11:571PubMedPubMedCentralCrossRef
46.
Epitropoulos AT, Donnenfeld ED, Shah ZA, Holland EJ, Gross M, Faulkner WJ et al (2016) Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea 35(9):1185–1191PubMedPubMedCentralCrossRef
47.
Chotikavanich S, de Paiva CS, de Li Q, Chen JJ, Bian F, Farley WJ et al (2009) Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 50(7):3203–3209PubMedPubMedCentralCrossRef
48.
Sambursky R, Davitt WF 3rd, Friedberg M, Tauber S (2014) Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease. Cornea 33(8):812–818PubMedCrossRef
49.
Malhotra C, Singh S, Chakma P, Jain AK (2015) Effect of oral omega-3 fatty acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: a prospective placebo-controlled study. Cornea 34(6):637–643PubMedCrossRef
50.
Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE (2017) A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology 124(1):43–52PubMedCrossRef
51.
Sahli E, Hosal BM, Zilelioglu G, Gulbahce R, Ustun H (2010) The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea 29(12):1412–1416PubMedCrossRef
52.
Erdinest N, Shmueli O, Grossman Y, Ovadia H, Solomon A (2012) Anti-inflammatory effects of alpha linolenic acid on human corneal epithelial cells. Invest Ophth Vis Sci. 53(8):4396–4406CrossRef
53.
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA et al (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21(2):325–332PubMedPubMedCentralCrossRef
54.
Zhang MJ, Spite M (2012) Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 32:203–227PubMedCrossRef
55.
Erdinest N, Ovadia H, Kormas R, Solomon A (2014) Anti-inflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro study. J Inflamm (Lond) 11(1):6CrossRef
56.
57.
Skarbez K, Priestley Y, Hoepf M, Koevary SB (2010) Comprehensive review of the effects of diabetes on ocular health. Expert Rev Ophthalmol 5(4):557–577PubMedPubMedCentralCrossRef
58.
59.
Hara M (1990) Pathology of diabetes mellitus. Nihon Rinsho 48(Suppl):209–214PubMed
60.
Priyadarsini S, Sarker-Nag A, Rowsey TG, Ma JX, Karamichos D (2016) Establishment of a 3D in vitro model to accelerate the development of human therapies against corneal diabetes. PLoS ONE 11(12):e0168845PubMedPubMedCentralCrossRef
61.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36(2):150–154PubMedCrossRef
62.
Stock K (2004) Multiple cerebral aneurysms in a patient with recurrent cardiac myxomas. A case report. Interv Neuroradiol 10(4):335–340PubMedCrossRef
63.
Diabetic Retinopathy Clinical Research Network, Writing Committee, Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M, Ferris FL 3rd, Glassman AR, Maturi RK, Stockdale CR, Topping TM (2011) Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 118(12):e5–14. doi:10.​1016/​j.​ophtha.​2011.​09.​058 PubMedCentralCrossRef
64.
65.
66.
Coppey LJ, Davidson EP, Obrosov A, Yorek MA (2015) Enriching the diet with menhaden oil improves peripheral neuropathy in streptozotocin-induced type 1 diabetic rats. J Neurophysiol 113(3):701–708PubMedCrossRef
67.
Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA (2000) Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 1(2):131–143PubMedPubMedCentralCrossRef
68.
Shevalye H, Yorek MS, Coppey LJ, Holmes A, Harper MM, Kardon RH et al (2015) Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J Neurophysiol 114(1):199–208PubMedPubMedCentralCrossRef
69.
Lee JE, Sun Y, Gjorstrup P, Pearlman E (2015) Inhibition of corneal inflammation by the resolvin E1. Invest Ophth Vis Sci 56(4):2728–2736CrossRef
70.
Yorek MS, Coppey LJ, Shevalye H, Obrosov A, Kardon RH, Yorek MA (2016) Effect of treatment with salsalate, menhaden oil, combination of salsalate and menhaden oil, or resolvin D1 of C57Bl/6J type 1 diabetic mouse on neuropathic endpoints. J Nutr Metab 2016:5905891PubMedPubMedCentralCrossRef
71.
Higgs GA, Salmon JA, Henderson B, Vane JR (1987) Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 84(5):1417–1420PubMedPubMedCentralCrossRef
72.
Davidson EP, Holmes A, Coppey LJ, Yorek MA (2015) Effect of combination therapy consisting of enalapril, alpha-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat. Eur J Pharmacol 765:258–267PubMedCrossRef
73.
Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT (2005) The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 3:11PubMedPubMedCentralCrossRef
74.
Greiner RC, Winter J, Nathanielsz PW, Brenna JT (1997) Brain docosahexaenoate accretion in fetal baboons: bioequivalence of dietary alpha-linolenic and docosahexaenoic acids. Pediatr Res 42(6):826–834PubMedCrossRef
75.
Anderson RE, Maude MB, McClellan M, Matthes MT, Yasumura D, LaVail MM (2002) Low docosahexaenoic acid levels in rod outer segments of rats with P23H and S334ter rhodopsin mutations. Mol Vis 8:351–358PubMed
76.
Bicknell IR, Darrow R, Barsalou L, Fliesler SJ, Organisciak DT (2002) Alterations in retinal rod outer segment fatty acids and light-damage susceptibility in P23H rats. Mol Vis 8:333–340PubMed
77.
Organisciak DT, Darrow RM, Jiang YL, Blanks JC (1996) Retinal light damage in rats with altered levels of rod outer segment docosahexaenoate. Invest Ophthalmol Vis Sci 37(11):2243–2257PubMed
78.
Moriguchi T, Salem N Jr (2003) Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J Neurochem 87(2):297–309PubMedCrossRef
79.
Litman BJ, Niu SL, Polozova A, Mitchell DC (2001) The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction. J Mol Neurosci 16(2–3):237–242 (discussion 79–84) PubMedCrossRef
80.
Kim HY, Akbar M, Lau A, Edsall L (2000) Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n−3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 275(45):35215–35223PubMedCrossRef
81.
Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N (2015) Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta 1851(4):397–413PubMedCrossRef
82.
83.
Liu M, Boussetta T, Makni-Maalej K, Fay M, Driss F, El-Benna J et al (2014) Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities. Lipids 49(1):49–57PubMedCrossRef
84.
Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, Petasis NA et al (2009) Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem 284(26):17877–17882PubMedPubMedCentralCrossRef
85.
Bazan NG (2006) Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 29(5):263–271PubMedCrossRef
86.
Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ et al (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26(4):1755–1765PubMedPubMedCentralCrossRef
87.
Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA et al (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484(7395):524–528PubMedPubMedCentralCrossRef
88.
Cortina MS, He J, Russ T, Bazan NG, Bazan HE (2013) Neuroprotectin D1 restores corneal nerve integrity and function after damage from experimental surgery. Invest Ophthalmol Vis Sci 54(6):4109–4116PubMedPubMedCentralCrossRef
89.
Li Z, Burns AR, Han L, Rumbaut RE, Smith CW (2011) IL-17 and VEGF are necessary for efficient corneal nerve regeneration. Am J Pathol 178(3):1106–1116PubMedPubMedCentralCrossRef
90.
Su DH, Wong TY, Wong WL, Saw SM, Tan DT, Shen SY et al (2008) Diabetes, hyperglycemia, and central corneal thickness: the Singapore Malay Eye Study. Ophthalmology 115(6):964–968PubMedCrossRef
91.
Lee JS, Oum BS, Choi HY, Lee JE, Cho BM (2006) Differences in corneal thickness and corneal endothelium related to duration in diabetes. Eye (Lond) 20(3):315–318CrossRef
92.
Schultz RO, Van Horn DL, Peters MA, Klewin KM, Schutten WH (1981) Diabetic keratopathy. Trans Am Ophthalmol Soc 79:180–199PubMedPubMedCentral
93.
Schultz RO, Peters MA, Sobocinski K, Nassif K, Schultz KJ (1983) Diabetic keratopathy as a manifestation of peripheral neuropathy. Am J Ophthalmol 96(3):368–371PubMedCrossRef
94.
Araki K, Ohashi Y, Kinoshita S, Hayashi K, Kuwayama Y, Tano Y (1994) Epithelial wound healing in the denervated cornea. Curr Eye Res 13(3):203–211PubMedCrossRef
95.
Baker KS, Anderson SC, Romanowski EG, Thoft RA, SundarRaj N (1993) Trigeminal ganglion neurons affect corneal epithelial phenotype. Influence on type VII collagen expression in vitro. Invest Ophthalmol Vis Sci 34(1):137–144PubMed
96.
Saini JS, Khandalavla B (1995) Corneal epithelial fragility in diabetes mellitus. Can J Ophthalmol 30(3):142–146PubMed
97.
Gekka M, Miyata K, Nagai Y, Nemoto S, Sameshima T, Tanabe T et al (2004) Corneal epithelial barrier function in diabetic patients. Cornea 23(1):35–37PubMedCrossRef
98.
Gobbels M, Spitznas M, Oldendoerp J (1989) Impairment of corneal epithelial barrier function in diabetics. Graefes Arch Clin Exp Ophthalmol 227(2):142–144PubMedCrossRef
99.
Borderie VM, Baudrimont M, Vallee A, Ereau TL, Gray F, Laroche L (2000) Corneal endothelial cell apoptosis in patients with Fuchs’ dystrophy. Invest Ophthalmol Vis Sci 41(9):2501–2505PubMed
100.
Jurkunas UV, Bitar MS, Funaki T, Azizi B (2010) Evidence of oxidative stress in the pathogenesis of fuchs endothelial corneal dystrophy. Am J Pathol 177(5):2278–2289PubMedPubMedCentralCrossRef
101.
Czarny P, Kasprzak E, Wielgorski M, Udziela M, Markiewicz B, Blasiak J et al (2013) DNA damage and repair in Fuchs endothelial corneal dystrophy. Mol Biol Rep 40(4):2977–2983PubMedCrossRef
102.
Stipanitzova H, Gerinec A (2003) Corneal dystrophies. Cesk Slov Oftalmol 59(5):359–367PubMed
103.
Bahn CF, Falls HF, Varley GA, Meyer RF, Edelhauser HF, Bourne WM (1984) Classification of corneal endothelial disorders based on neural crest origin. Ophthalmology 91(6):558–563PubMedCrossRef
104.
105.
Mandell RB, Polse KA, Brand RJ, Vastine D, Demartini D, Flom R (1989) Corneal hydration control in Fuchs’ dystrophy. Invest Ophthalmol Vis Sci 30(5):845–852PubMed
106.
McCartney MD, Wood TO, McLaughlin BJ (1989) Moderate Fuchs’ endothelial dystrophy ATPase pump site density. Invest Ophthalmol Vis Sci 30(7):1560–1564PubMed
107.
Zhang J, Patel DV (2015) The pathophysiology of Fuchs’ endothelial dystrophy—a review of molecular and cellular insights. Exp Eye Res 130:97–105PubMedCrossRef
108.
Azizi B, Ziaei A, Fuchsluger T, Schmedt T, Chen Y, Jurkunas UV (2011) p53-regulated increase in oxidative-stress–induced apoptosis in Fuchs endothelial corneal dystrophy: a native tissue model. Invest Ophthalmol Vis Sci 52(13):9291–9297PubMedPubMedCentralCrossRef
109.
Biswas S, Munier FL, Yardley J, Hart-Holden N, Perveen R, Cousin P et al (2001) Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum Mol Genet 10(21):2415–2423PubMedCrossRef
110.
Gottsch JD, Zhang C, Sundin OH, Bell WR, Stark WJ, Green WR (2005) Fuchs corneal dystrophy: aberrant collagen distribution in an L450W mutant of the COL8A2 gene. Invest Ophthalmol Vis Sci 46(12):4504–4511PubMedCrossRef
111.
Karamichos D, Hutcheon AE, Rich CB, Trinkaus-Randall V, Asara JM, Zieske JD (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608PubMedPubMedCentralCrossRef
112.
Price MO, Giebel AW, Fairchild KM, Price FW Jr (2009) Descemet’s membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. Ophthalmology 116(12):2361–2368PubMedCrossRef
113.
Price MO, Price FW (2007) Descemet’s stripping endothelial keratoplasty. Curr Opin Ophthalmol 18(4):290–294PubMedCrossRef
114.
Anijeet DR, Rachdan D, Shah S (2012) Visual improvement after corneal endothelial transplantation: are we seeing better? Br J Ophthalmol 96(3):309–310PubMedCrossRef
115.
Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M (2011) Liquid chromatography–mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol 708:247–257PubMedCrossRef
116.
Wilson SE, Bourne WM, Maguire LJ, Rahhal FM, Ribaudo RK, Kreutzer DL et al (1989) Aqueous humor composition in Fuchs’ dystrophy. Invest Ophthalmol Vis Sci 30(3):449–453PubMed
117.
Cabrerizo JUJA, de Mora MC, Vecino E, Melles G (2017) Changes in lipidomic profile of aqueous humor in Fuchs endothelial corneal dystrophy. Invest Ophth Vis Sci 56(7):1177
118.
Richardson MR, Segu ZM, Price MO, Lai X, Witzmann FA, Mechref Y et al (2010) Alterations in the aqueous humor proteome in patients with Fuchs endothelial corneal dystrophy. Mol Vis 16:2376–2383PubMedPubMedCentral
119.
Kim EC, Toyono T, Berlinicke CA, Zack DJ, Jurkunas U, Usui T et al (2017) Screening and characterization of drugs that protect corneal endothelial cells against unfolded protein response and oxidative stress. Invest Ophthalmol Vis Sci 58(2):892–900PubMedPubMedCentralCrossRef
120.
Holtz WA, Turetzky JM, Jong YJ, O’Malley KL (2006) Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99(1):54–69PubMedCrossRef
121.
Xue X, Piao JH, Nakajima A, Sakon-Komazawa S, Kojima Y, Mori K et al (2005) Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem 280(40):33917–33925PubMedCrossRef
122.
Tagawa Y, Hiramatsu N, Kasai A, Hayakawa K, Okamura M, Yao J et al (2008) Induction of apoptosis by cigarette smoke via ROS-dependent endoplasmic reticulum stress and CCAAT/enhancer-binding protein-homologous protein (CHOP). Free Radic Biol Med 45(1):50–59PubMedCrossRef
123.
Huang SS, Cheng H, Tang CM, Nien MW, Huang YS, Lee IH et al (2013) Anti-oxidative, anti-apoptotic, and pro-angiogenic effects mediate functional improvement by sonic hedgehog against focal cerebral ischemia in rats. Exp Neurol 247:680–688PubMedCrossRef
124.
Yesilot S, Ozer MK, Bayram D, Oncu M, Karabacak HI, Cicek E (2010) Effects of aspirin and nimesulide on tissue damage in diabetic rats. Cytokine 52(3):163–167PubMedCrossRef
125.
Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT et al (2004) Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 279(45):46384–46392PubMedCrossRef
126.
Okumura N, Kinoshita S, Koizumi N (2014) Cell-based approach for treatment of corneal endothelial dysfunction. Cornea 33(Suppl 11):S37–S41PubMedCrossRef
127.
Okumura N, Koizumi N, Ueno M, Sakamoto Y, Takahashi H, Tsuchiya H et al (2012) ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol 181(1):268–277PubMedCrossRef
128.
Okumura N, Ueno M, Koizumi N, Sakamoto Y, Hirata K, Hamuro J et al (2009) Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci 50(8):3680–3687PubMedCrossRef
129.
Peh GS, Beuerman RW, Colman A, Tan DT, Mehta JS (2011) Human corneal endothelial cell expansion for corneal endothelium transplantation: an overview. Transplantation 91(8):811–819PubMedCrossRef
130.
Ishino Y, Sano Y, Nakamura T, Connon CJ, Rigby H, Fullwood NJ et al (2004) Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. Invest Ophthalmol Vis Sci 45(3):800–806PubMedCrossRef
131.
Mimura T, Yamagami S, Yokoo S, Usui T, Tanaka K, Hattori S et al (2004) Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model. Invest Ophthalmol Vis Sci 45(9):2992–2997PubMedCrossRef
132.
Sumide T, Nishida K, Yamato M, Ide T, Hayashida Y, Watanabe K et al (2006) Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. FASEB J 20(2):392–394PubMed
133.
Koizumi N, Sakamoto Y, Okumura N, Okahara N, Tsuchiya H, Torii R et al (2007) Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophthalmol Vis Sci 48(10):4519–4526PubMedCrossRef
134.
Worthylake RA, Lemoine S, Watson JM, Burridge K (2001) RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154(1):147–160PubMedPubMedCentralCrossRef
135.
Worthylake RA, Burridge K (2003) RhoA and ROCK promote migration by limiting membrane protrusions. J Biol Chem 278(15):13578–13584PubMedCrossRef
136.
137.
Narumiya S, Tanji M, Ishizaki T (2009) Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28(1–2):65–76PubMedCrossRef
138.
Darlington JK, Adrean SD, Schwab IR (2006) Trends of penetrating keratoplasty in the United States from 1980 to 2004. Ophthalmology 113(12):2171–2175PubMedCrossRef
139.
Chen ES, Shamie N, Terry MA (2008) Descemet-stripping endothelial keratoplasty: improvement in vision following replacement of a healthy endothelial graft. J Cataract Refract Surg 34(6):1044–1046PubMedCrossRef
140.
Anshu A, Price MO, Price FW Jr (2013) Descemet stripping automated endothelial keratoplasty for Fuchs endothelial dystrophy-influence of graft diameter on endothelial cell loss. Cornea 32(1):5–8PubMedCrossRef
141.
Price FW Jr, Price MO (2005) Descemet’s stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refract Surg 21(4):339–345PubMed
Metadata
Title
The role of lipids in corneal diseases and dystrophies: a systematic review
Authors
Tyler G. Rowsey
Dimitrios Karamichos
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2017
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-017-0158-1

Other articles of this Issue 1/2017

Clinical and Translational Medicine 1/2017 Go to the issue

Review

Significance of long chain polyunsaturated fatty acids in human health

Review

Lipidomics and anti-trypanosomatid chemotherapy

Review

The role of heterogeneity in asthma: a structure-to-function perspective

Erratum

Expression of Concern to: Role of physiotherapy in the mobilization of patients with spinal cord injury undergoing human embryonic stem cells transplantation

Research

Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study

Commentary

Integrating phosphoproteomics into the clinical management of prostate cancer